Lisa Schoyer

Lisa Schoyer

Auto-generated profile, based on publicly available information

Lisa Schoyer

RASopathies Network USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AGAndrea M. Gross
Andrea M. Gross
MFMegan Frone
Megan Frone
KGKaren W. Gripp
Karen W. Gripp
BGBruce D. Gelb
Bruce D. Gelb
LSLisa Schoyer
Lisa Schoyer
MYMarielle E. Yohe
Marielle E. Yohe

15 April 2008 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
KRKatherine A. Rauen
Katherine A. Rauen
EHErin Hefner
Erin Hefner
KCKristin Carrillo
Kristin Carrillo
JTJill Taylor
Jill Taylor
LMLaure Messier
Laure Messier
LSLisa Schoyer
Lisa Schoyer

10 October 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
KRKatherine A. Rauen
Katherine A. Rauen
LSLisa Schoyer
Lisa Schoyer
LSLisa Schill
Lisa Schill
BSBeth Stronach
Beth Stronach
JAJohn Albeck
John Albeck
FMFrank McCormick
Frank McCormick

9 March 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
MKMaria I Kontaridis
Maria I Kontaridis
ARAmy Roberts
Amy Roberts
LSLisa Schill
Lisa Schill
LSLisa Schoyer
Lisa Schoyer
BSBeth Stronach
Beth Stronach
MZMartin Zenker
Martin Zenker
RASopathies are a group of genetic disorders that are caused by genes that affect the canonical Ras/mitogen‐activated protein kinase (MAPK) signaling pathway. Despite tremendous progress in understanding the molecular consequences of these genetic anomalies, little movement has been made in translating these findings to the clinic. This year, the seventh International RASopathies Symposium focused on expanding the research knowledge that we have gained over the years to enhance new discoveries in the field, ones that we hope can lead to effective therapeutic treatments. Indeed, for the first time, research efforts are finally being translated to the clinic, with compassionate use of Ras/MAPK pathway inhibitors for the treatment of RASopathies. This biannual meeting, organized by the RASopathies Network, brought together basic scientists, clinicians, clinician scientists, patients, advocates, and their families, as well as representatives from pharmaceutical companies and the National Institutes of Health. A history of RASopathy gene discovery, identification of new disease genes, and the latest research, both at the bench and in the clinic, were discussed.

15 November 2023 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
EPElizabeth I. Pierpont
Elizabeth I. Pierpont
ABAnton M. Bennett
Anton M. Bennett
LSLisa Schoyer
Lisa Schoyer
BSBeth Stronach
Beth Stronach
AAApril Anschutz
April Anschutz
GAGregor Andelfinger
Gregor Andelfinger
Germline pathogenic variants in the RAS/mitogen‐activated protein kinase (MAPK) signaling pathway are the molecular cause of RASopathies, a group of clinically overlapping genetic syndromes. RASopathies constitute a wide clinical spectrum characterized by distinct facial features, short stature, predisposition to cancer, and variable anomalies in nearly all the major body systems. With increasing global recognition of these conditions, the 8th International RASopathies Symposium spotlighted global perspectives on clinical care and research, including strategies for building international collaborations and developing diverse patient cohorts in anticipation of interventional trials. This biannual meeting, organized by RASopathies Network, was held in a hybrid virtual/in‐person format. The agenda featured emerging discoveries and case findings as well as progress in preclinical and therapeutic pipelines. Stakeholders including basic scientists, clinician‐scientists, practitioners, industry representatives, patients, and family advocates gathered to discuss cutting edge science, recognize current gaps in knowledge, and hear from people with RASopathies about the experience of daily living. Presentations by RASopathy self‐advocates and early‐stage investigators were featured throughout the program to encourage a sustainable, diverse, long‐term research and advocacy partnership focused on improving health and bringing treatments to people with RASopathies.

30 November 2024
Verified
Book Chapter
Closed access
PDF file
LSLisa Schoyer
Lisa Schoyer
BSBeth Stronach
Beth Stronach